1) Schöffski P, et al. Randomized, open-label, multicenter, phase 3 study of eribulin
versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma
(ADI). DGHO 2015; Abstract 258
2) Twelves C, et al. Efficacy and safety of eribulin in combination with capecitabine in
patients with metastatic breast cancer: an open-label phase II dose-confirmation
study. DGHO 2015; Abstract presented at DGHO 2015
3) Dobbie M, Long lasting disease stabilisation with Eribulin. DGHO 2015; Abstract
presented at DGHO 2015
4) SPC Halaven (updated June 2014). Available at:
http://www.medicines.org.uk/emc/medicine/24382/SPC/Halaven+0.44+mg+ml+solution+for+injection
Accessed: September 2015
5) Motzer R, Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE),
and LEN _ EVE in patients with metastatic renal cell carcinmoa (mRCC). DGHO 2015;
Abstract presented at DGHO 2015
6) Elisei R, et al. Subgroup Analysis According to Differentiated Thyroid Cancer
Histology in Phase 3 (SELECT) Trial of Lenvatinib. DGHO 2015; Abstract presented at
DGHO 2015
7) SPC Lenvima (updated May 2015). Available at:
http://www.medicines.org.uk/emc/medicine/30412 Accessed: September 2015
8) Macmillan. What are soft tissue sarcomas? Available at:
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/Aboutsofttissuesarcomas/Softtissuesarcomas.aspx
Accessed: September 2015
9) National Cancer Institute.
http://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page1
Accessed: September 2015
10) Cancer Research UK, Soft Tissue Sarcoma Incidence Statistics:
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/soft-tissue-sarcoma/incidence
Accessed: September 2015
11) ESMO Guidance:
http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Accessed:
July 2015
12) M. Schuichi, et al. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan. Current
Clinical Oncology. 2013; 233-234
13) H. Tsujii, et al. Carbon-Ion Radiotherapy: Principles, Practices, and Treatment
Planning. Springer. 2014; (XII)312:237
14) Fletcher et al. World Health Organization Classification of Tumours of Soft Tissue and
Bone (4th Edition). Lyon: IARC Press, 2013.
15) Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed
by Biochemical Characterization. ACS Med. Chem. Lett 2015; 6:89-94
16) Wu P et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug
Discovery Today 2015; 1-6
17) Schlumberger M, et al. Relationship Between Thyroid-Stimulating Hormone Levels and
Outcomes from the Randomized, Double-Blind, Phase 3 Study of (E7080) Lenvatinib in
Differentiated Cancer of the Thyroid (SELECT). Available at:
https://endo.confex.com/endo/2015endo/webprogram/Paper20459.html Accessed:
September 2015
18) Brito J et al. BMJ 2013; 347
19) Cabanillas ME, Dadu R. Optimizing therapy for radioactive iodine-refractory
differentiated thyroid cancer : Current state of the art and future directions.
Minerva Endocrinol. 2012 Dec; 37(4):335-356.
20) EUCAN 2015. http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35 Accessed: June
2015
21) Thyroid Cancer Basics. 2011. Available at: http://www.thyca.org Accessed: June
2015
22) Pacini F et al. ESMO Guidelines Working Group. Ann Oncol. 2012;23 (suppl 7)
:vii110-vii119.
Date of preparation: October 2015
Oncology-UK0054
CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller, 12 Oct. (0) - 7908-314-155 / +44(0)7951-078-795, Cressida_Robson@eisai.net /Ben_Speller@eisai.net; Tonic Life Communications: Alex Davies / EmmaCoughlan, +44-(0)7720-496-472 / +44-(0)7772-534-646,Alex.Davies@toniclc.com / Emma.Coughlan@toniclc.com
